

Supplementary Information

Advancement of NK cell-mediated pancreatic cancer therapy through high-throughput screening

Chung Hyeun Ma ^{1,†}, Hyun Hee Kim ^{2,†}, Jeong Woo Park ², In Kyong Shim ³,
Dae-Hee Lee ^{2,4,*}, Song Chul Kim ^{5,*}

✓ **Supplementary Figure S1.**

Western blot results and their original images for rosiglitazone-treated NK-92MI cells.

✓ **Supplementary Figure S2.**




The original uncropped blot images for the Western blot data presented in Figure 6.

✓ **Supplementary Figure S3.**

ELISA results from NK-92MI cell culture supernatants following rosiglitazone treatment.


All western blots include molecular weight markers using Bio-Rad Protein™ All Blue Prestained Protein Standards (catalog #1610373) and are presented as full, uncropped images to ensure transparency and reproducibility.

Supplementary Figure S1. Western blot results and their original images for rosiglitazone-treated NK-92MI cells.



This Western blot image includes the full, uncropped blot with molecular weight marker Protein™ All Blue Prestained Protein Standards (Bio-Rad, catalog #1610373).

Supplementary Figure S2. The original uncropped blot images for the Western blot data presented in Figure 6.



This Western blot image includes the full, uncropped blot with molecular weight marker Protein™ All Blue Prestained Protein Standards (Bio-Rad, catalog #1610373).

Supplementary Figure S3. ELISA results from NK-92MI cell culture supernatants following rosiglitazone treatment.

